(Q55206226)

25 June 2018

3 references

21 March 2019

25 April 2019

17 June 2019

Extraintestinal Manifestations of Inflammatory Bowel Disease. (English)

1 reference

25 June 2018

inflammatory bowel diseases

main subject

inflammation

0 references

biliary tract disease

3 references

21 March 2019

25 April 2019

17 June 2019

3 references

21 March 2019

25 April 2019

17 June 2019

3 references

21 March 2019

25 April 2019

17 June 2019

3 references

21 March 2019

25 April 2019

17 June 2019

musculoskeletal disorder

3 references

21 March 2019

25 April 2019

17 June 2019

3 references

21 March 2019

25 April 2019

17 June 2019

4

1 reference

25 June 2018

Gerhard Rogler

6

object named as

Gerhard Rogler

1 reference

25 June 2018

5

Alexander Navarini

1 reference

25 June 2018

author name string

Stephan R Vavricka

1

1 reference

25 June 2018

Alain Schoepfer

2

1 reference

25 June 2018

Michael Scharl

3

1 reference

25 June 2018

publication date

1 August 2015

4 references

25 June 2018

Inflammatory Bowel Diseases

21 March 2019

25 April 2019

17 June 2019

4 references

25 June 2018

21 March 2019

25 April 2019

17 June 2019

21

1 reference

25 June 2018

issue

8

1 reference

25 June 2018

page(s)

1982-1992

1 reference

25 June 2018

Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Biologics for extraintestinal manifestations of IBD.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Extraintestinal manifestations and complications in IBD.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Cutaneous manifestations of gastrointestinal disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Treatment of extraintestinal manifestations in inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

IBD and arthropathies: a practical approach to its diagnosis and management

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

30 June 2018

Pyoderma gangraenosum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Rheumatic manifestations of inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Ulcerative colitis and Sweet's syndrome: a case report and review of the literature

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Adalimumab therapy for recalcitrant pyoderma gangrenosum

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Adalimumab in the therapy of uveitis in childhood

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Extraintestinal manifestations and complications in inflammatory bowel diseases

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, and Colon Cancer

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Extraintestinal manifestations in inflammatory bowel disease.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Retrospective case review of pediatric patients with uveitis treated with infliximab

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Important cutaneous manifestations of inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Management of peristomal pyoderma gangrenosum

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Anti-TNF-alpha therapy for sight threatening uveitis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Ocular manifestations of inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Extraintestinal complications of inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Inflammatory bowel disease and spondylarthropathy

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Muscoloskeletal manifestations in inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Current use of biologicals for the treatment of spondyloarthropathies

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Factors influencing the relapse of patients with inflammatory bowel disease.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Genetic markers may predict disease behavior in patients with ulcerative colitis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

The sacroiliac joint in the spondyloarthropathies.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Clinical patterns of familial inflammatory bowel disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Treatment of pyoderma gangrenosum

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Erythema nodosum progressing to pyoderma gangrenosum as a complication of Crohn's disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Neutrophilic vascular reactions

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Sweet's syndrome and pyoderma gangrenosum associated with ulcerative colitis.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Sweet's syndrome associated with Crohn's disease.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Extracolonic diagnoses in ulcerative colitis: an epidemiological study.

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Sweet's syndrome: a clinicopathologic review of twenty-nine cases

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Relationship of inflammatory bowel disease and primary sclerosing cholangitis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Clinical patterns in Crohn's disease: a statistical study of 615 cases

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

The histocompatibility antigen (HL-A 27) and disease

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27)

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

THE EXTRA-INTESTINAL COMPLICATIONS OF CROHNʼS DISEASE AND ULCERATIVE COLITIS: A STUDY OF 700 PATIENTS

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort

30 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Infliximab as a treatment for recalcitrant pyoderma gangrenosum.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Infliximab in the treatment of refractory posterior uveitis

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4511685

Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics

13 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1097%2FMIB.0000000000000392

Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1097%2FMIB.0000000000000392

Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Refractory chronic erythema nodosum successfully treated with adalimumab

1 reference

12 December 2020

Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab

1 reference

12 December 2020

The effect of infliximab on extraintestinal manifestations of Crohn's disease

1 reference

12 December 2020

Skin manifestations of inflammatory bowel disease

1 reference

12 December 2020

Extraintestinal manifestations of inflammatory bowel disease

1 reference

12 December 2020

The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody

1 reference

12 December 2020

Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease

1 reference

12 December 2020

The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study

1 reference

12 December 2020

Oral metronidazole, an effective treatment for Sweet's syndrome in a patient with associated inflammatory bowel disease

1 reference

12 December 2020

Favorable response to high-dose infliximab for refractory childhood uveitis

1 reference

12 December 2020

Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms

1 reference

12 December 2020

Leucocytoclastic vasculitis in severe ulcerative colitis

1 reference

12 December 2020

Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease

1 reference

12 December 2020

Infliximab for peristomal pyoderma gangrenosum

1 reference

12 December 2020

Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease

1 reference

12 December 2020

Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab

1 reference

12 December 2020

Azathioprine-induced Sweet's syndrome in Crohn's disease

1 reference

12 December 2020

Treatment of chronic erythema nodosum with infliximab

1 reference

12 December 2020

Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

1 reference

12 December 2020

Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum

1 reference

12 December 2020

Treatment of pyoderma gangrenosum with infliximab in Crohn's disease

1 reference

12 December 2020

Adalimumab for treatment of pyoderma gangrenosum

1 reference

12 December 2020

[Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab]

1 reference

12 December 2020

Hepatobiliary manifestations of inflammatory bowel disease

1 reference

12 December 2020

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

12 December 2020

Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis

1 reference

12 December 2020

Primary sclerosing cholangitis

1 reference

12 December 2020

Clinical use of Infliximab in Crohn's disease: the Edinburgh experience

1 reference

12 December 2020

Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease

1 reference

12 December 2020

[Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis]

1 reference

12 December 2020

1 reference

12 December 2020

Crohn's disease arthritis treated with infliximab: an open trial in four patients

1 reference

12 December 2020

Ocular manifestations of inflammatory bowel disease

1 reference

12 December 2020

Arthritic manifestations of inflammatory bowel disease

1 reference

12 December 2020

Periodontitis and gingivitis in inflammatory bowel disease: a case-control study

1 reference

12 December 2020

Clinical features and treatment of peristomal pyoderma gangrenosum

1 reference

12 December 2020

Pyoderma gangrenosum and its treatment

1 reference

12 December 2020

Extraintestinal manifestations of inflammatory bowel disease

1 reference

12 December 2020

Dermatologic manifestations of Crohn disease in children: response to infliximab

1 reference

12 December 2020

Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease

1 reference

12 December 2020

Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease

1 reference

12 December 2020

Clinicopathologic features of the syndrome of primary sclerosing cholangitis

1 reference

12 December 2020

Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease

1 reference

12 December 2020

Anti-TNF therapies in the management of acute and chronic uveitis

1 reference

12 December 2020

Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study

1 reference

12 December 2020

10.1097/MIB.0000000000000392

Identifiers

DOI

1 reference

25 June 2018

PMC publication ID

4511685

1 reference

25 June 2018

PubMed publication ID

26154136

1 reference

25 June 2018